GlassScriptPhysician profile
Aurora D Lopez
NPI 1821418575
$1,560.92
in general payments reported to CMS, 2019-2025
25 companies · $524 in 2025
The $524 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $95.20 · 2022: $62.40 · 2024: $633 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.60 |
| Education | $257.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher Scientific Company L.L.C. | $257.89 | 2024 | Procalcitonin |
| Organon LLC | $221.15 | 2024-2025 | Nexplanon |
| Shield Therapeutics INC | $155.94 | 2024-2025 | |
| Pfizer INC. | $102.81 | 2022-2025 | |
| Astellas Pharma US INC | $91.18 | 2024-2025 | Veozah |
| Mylan Pharmaceuticals INC. | $76.35 | 2019-2020 | |
| Innovation Technologies INC | $74.56 | 2025 | Irrisept |
| Mayne Pharma Commercial LLC | $73.71 | 2025 | |
| Coopersurgical, INC. | $73.47 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.86 | 2019-2024 | |
| Sage Therapeutics, LLC | $55.74 | 2024-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $45.33 | 2019 | |
| Abbvie INC. | $40.63 | 2019-2020 | |
| Therapeuticsmd, INC. | $35.22 | 2019-2020 | |
| Davol INC. | $33.04 | 2025 | Arista |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.20 | 2019 | |
| Millicent US INC | $21.06 | 2022 | |
| Lupin INC. | $17.57 | 2019 | |
| Lilly USA, LLC | $16.72 | 2025 | Zepbound |
| Biogen, INC. | $15.57 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $14.97 | 2024 | Slynd |
| Boston Scientific Corporation | $14.34 | 2019 | |
| Merck Sharp & Dohme LLC | $14.16 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.01 | 2020 | |
| Channel Medsystems, INC. | $11.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.